Peer-Reviewed Publications

      A 28-day rat inhalation study with an integrated molecular toxicology endpoint demonstrates reduced exposure effects for a prototypic modified risk tobacco product compared with conventional cigarettes

      Kogel, U.; Schlage, W. K.; Martin, F.; Xiang, Y.; Ansari, S.; Leroy, P.; Vanscheeuwijck, P.; Gebel, S.; Buettner, A.; Wyss, C.; Esposito, M.; Hoeng, J.; Peitsch, M. C.

      Published
      Mar 11, 2014
      DOI
      10.1016/j.fct.2014.02.034
      PMID
      24632068
      Link to publication
      Topic
      Summary

      Towards a systems toxicology-based risk assessment, we investigated molecular perturbations accompanying histopathological changes in a 28-day rat inhalation study combining transcriptomics with classical histopathology. We demonstrated reduced biological activity of a prototypic modified risk tobacco product (pMRTP) compared with the reference research cigarette 3R4F. Rats were exposed to filtered air or to three concentrations of mainstream smoke (MS) from 3R4F, or to a high concentration of MS from a pMRTP. Histopathology revealed concentration-dependent changes in response to 3R4F that were irritative stress-related in nasal and bronchial epithelium, and inflammation-related in the lung parenchyma. For pMRTP, significant changes were seen in the nasal epithelium only. Transcriptomics data were obtained from nasal and bronchial epithelium and lung parenchyma. Concentration-dependent gene expression changes were observed following 3R4F exposure, with much smaller changes for pMRTP. A computational-modeling approach based on causal models of tissue-specific biological networks identified cell stress, inflammation, proliferation, and senescence as the most perturbed molecular mechanisms. These perturbations correlated with histopathological observations. Only weak perturbations were observed for pMRTP. In conclusion, a correlative evaluation of classical histopathology together with gene expression-based computational network models may facilitate a systems toxicology-based risk assessment, as shown for a pMRTP.

      Related Publications

      Indoor Air Chemistry - An exploratory study on e-cigarette shows no negative impact on indoor air quality

      Aerosol Chemistry

      Indoor air chemistry - An exploratory study on e-cigarette shows no negative impact on indoor air quality

      Aerosol Chemistry

      Computer-Assisted Structure Identification (CASI) for high-throughput identification of small molecules using GC×GC-HRAM-TOFMS high-resolution accurate mass spectrometry

      Aerosol Chemistry

      Computer-Assisted Structure Identification (CASI) for high-throughput identification of small molecules using GC×GC-HRAM-TOFMS high-resolution accurate mass spectrometry

      Aerosol Chemistry

      Air quality assessment during indoor use of the Tobacco Heating System 2.2

      Aerosol Chemistry

      Air quality assessment during indoor use of the Tobacco Heating System THS 2.2

      Aerosol Chemistry

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.